International Journal of Hepatology Research

ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2023; 5(1): 27-30
www.hepatologyjournal.in
Received: 30-01-2023
Accepted: 27-02-2023

Dr. Catarina Costa
Department of Hepatology, University of Porto, Porto, Portugal

Corresponding Author:
Dr. Catarina Costa
Department of Hepatology, University of Porto, Porto, Portugal

Advances in non-invasive diagnostic tools for hepato-biliary diseases

Dr. Catarina Costa

DOI: https://doi.org/10.33545/26646595.2023.v5.i1a.22

Abstract
Hepato-biliary diseases, encompassing conditions affecting the liver, bile ducts, and gallbladder, are among the most common health concerns worldwide. Traditional diagnostic methods, such as liver biopsy, are invasive and carry significant risks. In recent years, advancements in non-invasive diagnostic tools have offered safer, more accurate, and efficient alternatives for diagnosing and monitoring hepato-biliary diseases. This review explores the recent advances in non-invasive diagnostic methods, including imaging techniques, serum biomarkers, and genetic tests, with a focus on their clinical utility, accuracy, and limitations. Additionally, we highlight emerging technologies and their potential to revolutionize hepato-biliary disease management.

Keywords: Non-invasive diagnostics, hepato-biliary diseases, biomarkers, imaging, elastography, liver disease

Introduction
Hepato-biliary diseases encompass a diverse group of conditions that affect the liver, bile ducts, and gallbladder, with hepatocellular carcinoma (HCC), cirrhosis, cholangiocarcinoma, and gallstones being among the most common. These diseases present significant health challenges worldwide, contributing to substantial morbidity and mortality. Early diagnosis is a critical factor in the successful management and treatment of these conditions, as many hepato-biliary diseases, particularly liver cancer, progress silently without symptoms until they reach an advanced stage. Detecting these diseases early can improve survival rates, slow disease progression, and prevent complications such as liver failure or the spread of cancer.

Traditionally, the diagnosis of liver diseases has relied heavily on liver biopsy, which has long been considered the gold standard for assessing liver fibrosis, cirrhosis, and diagnosing conditions like hepatocellular carcinoma. Liver biopsy involves the extraction of a small piece of liver tissue, which is then analyzed histologically to evaluate the extent of liver damage or the presence of malignancy. However, liver biopsy is an invasive procedure associated with significant drawbacks. It carries risks of complications, including pain, bleeding, and infection. Additionally, because biopsy samples represent only a small portion of the liver, there is a potential for sampling errors, where the biopsy may not capture the most affected areas of the liver, leading to inaccurate diagnoses.

In light of these limitations, there has been a growing demand for non-invasive diagnostic methods that can provide similar or even superior diagnostic accuracy without the risks and discomfort associated with invasive procedures like biopsy. This demand has driven significant advancements in medical imaging, biomarker development, and molecular testing techniques, offering alternative ways to diagnose and monitor hepato-biliary diseases more safely and efficiently.

Non-invasive techniques are particularly appealing in the diagnosis of liver fibrosis and cirrhosis, as well as in the detection and monitoring of liver cancer. For example, ultrasound-based elastography, such as transient elastography (commonly known as FibroScan), measures liver stiffness, which correlates with the degree of fibrosis in liver diseases. It has emerged as a highly effective and widely used tool in clinical practice. Magnetic resonance elastography (MRE) offers even more detailed imaging, providing a non-invasive alternative for fibrosis assessment, with the added advantage of being more accurate in patients with obesity or other conditions that limit ultrasound's effectiveness.

In addition to imaging techniques, the development of blood-based biomarkers has further expanded the non-invasive diagnostic landscape for hepato-biliary diseases. Serum markers, such as alpha-fetoprotein (AFP), have been used in screening for hepatocellular carcinoma, though with limited sensitivity and specificity. However, newer biomarker panels and algorithms, such as the Fibrosis-4 (FIB-4) index and the aspartate aminotransferase-to-platelet ratio index (APRI), are being used to assess liver fibrosis non-invasively in patients with chronic liver disease. These markers are inexpensive, accessible, and can reduce the need for liver biopsy in many cases.

The integration of genetic and molecular testing, enabled by next-generation sequencing (NGS) technologies, has also transformed the diagnosis and management of hepato-biliary diseases. NGS allows for the identification of specific genetic mutations associated with liver cancer, as well as hereditary liver diseases such as Wilson's disease, hereditary hemochromatosis, and alpha-1 antitrypsin deficiency. By analyzing genetic mutations, clinicians can now detect these diseases earlier, predict their progression, and tailor treatment strategies to individual patients based on their molecular profiles. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) in the blood, offers a promising non-invasive approach for monitoring liver cancer progression and detecting minimal residual disease after treatment.

As non-invasive diagnostic tools continue to evolve, they offer significant benefits over traditional methods. These techniques not only reduce patient discomfort and the risk of complications but also allow for repeated measurements and ongoing monitoring of disease progression over time. They are particularly useful in high-risk populations, such as patients with chronic viral hepatitis or cirrhosis, who require frequent monitoring to detect early signs of liver cancer or worsening fibrosis.

Objective

The objective of this paper is to explore the role of genetic and molecular testing in the diagnosis, prognosis, and treatment of hepato-biliary diseases, with a focus on improving early detection and personalized treatment strategies.

Advanced Imaging Techniques

Ultrasound elastography is a non-invasive imaging technique that measures liver stiffness, which correlates with the degree of fibrosis in conditions such as cirrhosis. Two main types of elastography are commonly used: transient elastography (TE) and acoustic radiation force impulse (ARFI) imaging. TE, often known by the trade name FibroScan, is widely used in clinical practice for staging liver fibrosis and monitoring disease progression. It has been shown to be accurate in detecting advanced fibrosis and cirrhosis with a high negative predictive value for excluding significant fibrosis in patients with chronic liver disease (Castera *et al*., 2012). ARFI imaging, which integrates elastography into conventional ultrasound, allows real-time liver stiffness measurement while performing a standard ultrasound examination (Bota *et al*., 2013). Both methods offer rapid, non-invasive assessment of fibrosis and are gaining widespread acceptance. Magnetic resonance elastography (MRE) is another non-invasive imaging modality that provides a detailed assessment of liver stiffness and fibrosis. Studies have demonstrated that MRE is more accurate than ultrasound elastography in detecting early-stage liver fibrosis, especially in obese patients where ultrasound techniques may be limited (Yin *et al*., 2016). MRE also has the advantage of being able to assess other organs, such as the pancreas and spleen, and can be used to evaluate the full extent of fibrosis in patients with hepato-biliary diseases.

Contrast-enhanced ultrasound (CEUS) is a newer imaging technique that uses micro bubble contrast agents to enhance visualization of blood flow and tissue vascularization. CEUS has been shown to be particularly useful in diagnosing focal liver lesions and differentiating between benign and malignant lesions. It is also effective in monitoring the response of liver tumors to treatments such as ablation and chemotherapy (Claudon *et al*., 2013). CEUS is non-invasive, safe, and does not involve ionizing radiation, making it an appealing option for repeated assessments.

Serum Biomarkers

Alpha-fetoprotein (AFP) has been used as a biomarker for hepatocellular carcinoma (HCC) for several decades. Elevated AFP levels are associated with HCC, though they are not specific to the disease and can also be raised in conditions such as hepatitis and cirrhosis. While AFP alone has limited sensitivity and specificity for HCC detection, combining it with imaging modalities improves diagnostic accuracy. Studies suggest that AFP remains a useful biomarker when used in conjunction with imaging, particularly in high-risk populations (Lok *et al*., 2010).

Serum biomarkers such as the FIB-4 index and the aspartate aminotransferase to platelet ratio index (APRI) are widely used to assess liver fibrosis in patients with chronic liver disease. FIB-4 combines age, AST, ALT, and platelet count to estimate fibrosis, while APRI uses AST and platelet count. Both markers are non-invasive, inexpensive, and easily accessible, making them valuable tools for assessing fibrosis without the need for liver biopsy. Numerous studies have shown that FIB-4 and APRI have good predictive value for advanced fibrosis and cirrhosis, although they are less reliable for detecting early-stage fibrosis (Sterling *et al*., 2006).

Cytokeratin-18 (CK-18) is a promising biomarker for liver cell apoptosis, which is commonly elevated in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). CK-18 has been investigated as a potential non-invasive marker for diagnosing NAFLD and distinguishing between simple steatosis and NASH. While CK-18 shows potential, it is not yet widely used in clinical practice due to variability in test results and the need for further validation (Feldstein *et al*., 2009).

Genetic and Molecular Testing

Genetic and molecular testing has revolutionized the understanding, diagnosis, and treatment of various hepato-biliary diseases, particularly liver cancer. The advent of these testing methods has allowed for the identification of specific genetic mutations, molecular markers, and pathways associated with the development and progression of diseases like hepatocellular carcinoma (HCC), cholangiocarcinoma, and hereditary liver diseases. By focusing on the genetic underpinnings of these conditions,

clinicians can now provide more personalized treatment plans and enhance early detection efforts, while researchers can better understand the biology of these diseases. One of the primary applications of genetic testing in liver cancer is the identification of mutations in key oncogenes and tumor suppressor genes. Mutations in the TERT promoter, TP53, CTNNB1 (beta-catenin), and AXIN1 genes are commonly associated with HCC. These mutations influence critical pathways, such as telomere maintenance (TERT), DNA repair (TP53), and Wnt/β-catenin signaling (CTNNB1). The identification of these mutations through next-generation sequencing (NGS) and other molecular techniques not only helps in early diagnosis but also serves as prognostic markers. For example, TP53 mutations are often associated with poor prognosis, while CTNNB1 mutations have been linked to better outcomes in certain patient groups. This genetic information enables stratification of patients into risk categories and helps guide treatment decisions, such as the use of targeted therapies or immunotherapy. Genetic testing also plays a significant role in identifying hereditary liver diseases. Diseases such as hereditary hemochromatosis, Wilson's disease, and alpha-1 antitrypsin deficiency are caused by specific genetic mutations that lead to the accumulation of toxic substances in the liver. For instance, hereditary hemochromatosis is linked to mutations in the HFE gene, leading to excessive iron accumulation in the liver, which can result in cirrhosis and HCC if untreated. Genetic testing for these mutations allows for early diagnosis, which is crucial for initiating appropriate management strategies, such as phlebotomy in the case of hereditary hemochromatosis, before the onset of severe liver damage. Molecular testing also aids in identifying biomarkers that can predict the response to certain therapies. In liver cancer, molecular testing is used to detect mutations or alterations in pathways that are actionable targets for precision medicine. For example, the detection of mutations in the PI3K/AKT/mTOR pathway can guide the use of inhibitors targeting this pathway. Additionally, immunotherapy has become a promising treatment for liver cancer, and molecular markers such as microsatellite instability (MSI) and tumor mutational burden (TMB), which can be identified through genetic testing, have been shown to predict the response to immune checkpoint inhibitors. By identifying these molecular signatures, clinicians can select patients who are most likely to benefit from these therapies, optimizing treatment outcomes and minimizing unnecessary toxicity.

In addition to its role in diagnosis and prognosis, genetic testing is becoming increasingly important for monitoring disease progression and recurrence in liver cancer. One of the most exciting advancements in this area is the use of liquid biopsy, which involves the analysis of circulating tumor DNA (ctDNA) in the bloodstream. Liquid biopsy allows for the non-invasive monitoring of genetic mutations and alterations in real-time, providing insights into tumor evolution and the emergence of resistance to therapies. This technique is particularly useful for patients with advanced liver cancer who require close monitoring of their treatment response. By tracking changes in ctDNA, clinicians can adjust therapies as needed to overcome resistance and improve long-term outcomes.

The application of genetic and molecular testing in the context of liver diseases extends beyond cancer. In conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), genetic predisposition plays a crucial role. Studies have identified polymorphisms in genes such as PNPLA3, TM6SF2, and MBOAT7, which are associated with an increased risk of developing liver inflammation, fibrosis, and ultimately cirrhosis. Testing for these genetic variants can help identify individuals at higher risk for disease progression, allowing for earlier intervention and lifestyle modifications to prevent liver damage.

While genetic and molecular testing offers immense promise, there are challenges to its widespread adoption in clinical practice. The cost of these tests, particularly next-generation sequencing, remains relatively high, although costs are decreasing with technological advancements. Additionally, the interpretation of genetic data, especially variants of unknown significance (VUS), can be complex and requires specialized expertise. It is often challenging to determine the clinical relevance of certain mutations, as not all genetic alterations contribute to disease progression. Furthermore, the ethical implications of genetic testing, such as patient consent and the handling of incidental findings, must be carefully managed to ensure that patients receive appropriate counseling and support.

In conclusion, genetic and molecular testing has become an integral part of diagnosing and managing hepato-biliary diseases. The ability to detect genetic mutations and molecular markers enables earlier diagnosis, personalized treatment, and better monitoring of disease progression. While challenges remain, particularly in terms of cost and data interpretation, ongoing advancements in genetic technologies are likely to further improve the utility of these tests, leading to better patient outcomes in hepato-biliary diseases.

Conclusion

In conclusion, genetic and molecular testing has significantly advanced the diagnosis, prognosis, and treatment of hepato-biliary diseases, particularly liver cancer. Through the identification of key genetic mutations and molecular markers, these testing methods have facilitated early detection, guided personalized treatment strategies, and provided valuable insights into tumor evolution and resistance mechanisms. Techniques like next-generation sequencing (NGS) and liquid biopsy have proven invaluable in uncovering genetic drivers of disease, offering non-invasive monitoring options, and enabling precision medicine approaches tailored to individual patients. While challenges remain, such as the cost of testing and the complexity of interpreting genetic data, the ongoing evolution of genetic and molecular testing technologies promises to further enhance their clinical utility. As the adoption of these techniques continues to grow, genetic testing will likely play an increasingly critical role in the comprehensive management of hepato-biliary diseases, leading to earlier interventions, more targeted treatments, and improved patient outcomes.

References

1. Curry MP, Jeffers LJ. Laboratory tests, noninvasive markers of fibrosis, liver biopsy, and laparoscopy. Schiff's Diseases of the Liver; c2017 Oct 25, p. 17-37.
2. Lee SH, Song SY. Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and

Molecular Classifications. Cancers. 2024 May 1;16(9):1761.
3. Ravaioli F, Colecchia A, Alemanni LV, Vestito A, Dajti E, Marasco G, *et al*. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. Expert review of gastroenterology & hepatology. 2019 May 4;13(5):463-484.
4. Levy AD. Noninvasive imaging approach to patients with suspected hepatobiliary disease. Techniques in vascular and interventional radiology. 2001 Sep 1;4(3):132-140.
5. Bali MA, Pezzullo M, Pace E, Morone M. Benign biliary diseases. European journal of radiology. 2017 Aug 1;93:217-228.
6. Sugimoto M. Recent advances in visualization, imaging, and navigation in hepatobiliary and pancreatic sciences. Journal of Hepato-Biliary-Pancreatic Sciences. 2010 Sep;17(5):574-576.
7. Thabut D, Weil D, Bouzbib C, Rudler M, Cassinotto C, Castéra L, *et al*. Non-invasive diagnosis and follow-up of portal hypertension. Clinics and Research in Hepatology and Gastroenterology. 2022 Oct 1;46(8):101767.
8. Mauro A, Mazza S, Scalvini D, Lusetti F, Bardone M, Quaretti P, *et al*. The Role of Cholangioscopy in Biliary Diseases. Diagnostics. 2023 Sep 13;13(18):2933.